Black Diamond Therapeutics Inc (BDTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Black Diamond Therapeutics Inc (BDTX) has a cash flow conversion efficiency ratio of -0.098x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.23 Million) by net assets ($104.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Black Diamond Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Black Diamond Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Black Diamond Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Black Diamond Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Black Diamond Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Samyang Packaging
KO:272550
|
0.045x |
|
Immobile
WAR:GKI
|
0.215x |
|
Tethys Petroleum Ltd
V:TPL
|
0.112x |
|
CI Holdings Bhd
KLSE:2828
|
0.112x |
|
Adverum Biotechnologies Inc
NASDAQ:ADVM
|
0.505x |
|
Yangarra Resources Ltd
TO:YGR
|
0.035x |
|
Her Chee Industrial Co Ltd
TWO:8937
|
-0.012x |
|
Synergy Green Industries Limited
NSE:SGIL
|
0.056x |
Annual Cash Flow Conversion Efficiency for Black Diamond Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Black Diamond Therapeutics Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Black Diamond Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $112.21 Million | $29.61 Million | 0.264x | +135.28% |
| 2024-12-31 | $83.28 Million | $-62.30 Million | -0.748x | -30.89% |
| 2023-12-31 | $116.74 Million | $-66.72 Million | -0.572x | +22.28% |
| 2022-12-31 | $115.69 Million | $-85.08 Million | -0.735x | -43.85% |
| 2021-12-31 | $195.90 Million | $-100.15 Million | -0.511x | -201.71% |
| 2020-12-31 | $307.76 Million | $-52.15 Million | -0.169x | -132.38% |
| 2019-12-31 | $-47.16 Million | $-24.67 Million | 0.523x | -3.81% |
| 2018-12-31 | $-15.54 Million | $-8.45 Million | 0.544x | +54.44% |
| 2017-12-31 | $-6.67 Million | $-2.35 Million | 0.352x | -- |
About Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutan… Read more